Search Results for: Adults

COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune rheumatic Diseases (COVIAAD): safety, immunogenicity and antibody persistence at 12 months following Moderna Spikevax primary series.

COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune rheumatic Diseases (COVIAAD): safety, immunogenicity and antibody persistence at 12 months following Moderna Spikevax primary series.

Coronavirus Literature
Publication date: Nov 29, 2023 To assess the safety, immunogenicity and cellular responses following the Moderna Spikevax primary series in rheumatic disease. We conducted a 12-month, prospective, non-randomised, open-label, comparative ... Read more
COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune rheumatic Diseases (COVIAAD): safety, immunogenicity and antibody persistence at 12 months following Moderna Spikevax primary series.

COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune rheumatic Diseases (COVIAAD): safety, immunogenicity and antibody persistence at 12 months following Moderna Spikevax primary series.

Coronavirus Literature
Publication date: Nov 29, 2023 To assess the safety, immunogenicity and cellular responses following the Moderna Spikevax primary series in rheumatic disease. We conducted a 12-month, prospective, non-randomised, open-label, comparative ... Read more
COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune rheumatic Diseases (COVIAAD): safety, immunogenicity and antibody persistence at 12 months following Moderna Spikevax primary series.

COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune rheumatic Diseases (COVIAAD): safety, immunogenicity and antibody persistence at 12 months following Moderna Spikevax primary series.

Coronavirus Literature
Publication date: Nov 29, 2023 To assess the safety, immunogenicity and cellular responses following the Moderna Spikevax primary series in rheumatic disease. We conducted a 12-month, prospective, non-randomised, open-label, comparative ... Read more